Barclays Begins Coverage on Masimo (MASI)
Barclays began coverage on shares of Masimo (NASDAQ:MASI) in a research report issued on Friday, MarketBeat reports. The brokerage set an “overweight” rating and a $97.00 price target on the medical equipment provider’s stock. Barclays’ price target points to a potential upside of 9.79% from the stock’s current price.
Several other analysts also recently weighed in on MASI. Piper Jaffray Companies reiterated a “hold” rating and issued a $91.00 price objective on shares of Masimo in a research report on Thursday, March 1st. Zacks Investment Research downgraded Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub upgraded Masimo from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $101.00.
Shares of Masimo (NASDAQ MASI) opened at $88.35 on Friday. The firm has a market capitalization of $4,660.00, a P/E ratio of 28.14, a P/E/G ratio of 2.27 and a beta of 0.91. Masimo has a 12-month low of $80.69 and a 12-month high of $104.71.
In related news, Director Sanford Fitch sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $90.00, for a total transaction of $180,000.00. Following the completion of the transaction, the director now owns 70,249 shares in the company, valued at $6,322,410. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Yongsam Lee sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $92.95, for a total value of $929,500.00. Following the transaction, the executive vice president now owns 79,000 shares of the company’s stock, valued at approximately $7,343,050. The disclosure for this sale can be found here. Insiders sold 24,000 shares of company stock valued at $2,177,340 in the last quarter. Corporate insiders own 16.60% of the company’s stock.
Several institutional investors have recently made changes to their positions in MASI. USA Mutuals Advisors Inc. bought a new position in shares of Masimo during the fourth quarter valued at approximately $110,000. SeaCrest Wealth Management LLC bought a new position in shares of Masimo during the fourth quarter valued at approximately $116,000. Advisors Preferred LLC bought a new position in shares of Masimo during the fourth quarter valued at approximately $158,000. DekaBank Deutsche Girozentrale raised its holdings in shares of Masimo by 78.3% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock valued at $182,000 after acquiring an additional 925 shares in the last quarter. Finally, MANA Advisors LLC bought a new position in shares of Masimo during the fourth quarter valued at approximately $227,000. Institutional investors own 81.48% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/03/11/barclays-begins-coverage-on-masimo-masi.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.